As the Director of the Protein Biochemistry group at Amgen, Stephen Thibault plays a pivotal role in advancing the company's Discovery Research initiatives. With a strong focus on recombinant protein expression and purification, Stephen leads a talented team that employs a variety of expression systems,...
As the Director of the Protein Biochemistry group at Amgen, Stephen Thibault plays a pivotal role in advancing the company's Discovery Research initiatives. With a strong focus on recombinant protein expression and purification, Stephen leads a talented team that employs a variety of expression systems, including E. coli, insect cells (via baculovirus), yeast, and mammalian cells. This diverse toolkit allows the group to produce high-quality proteins that are essential for both large and small molecule drug discovery programs.
Under Stephen's leadership, the team is dedicated to ensuring that all proteins undergo rigorous quality control processes, which are critical for their use in target validation and assay development. His expertise in molecular biology and protein expression techniques enables the group to tackle complex challenges in drug development, particularly in the context of monoclonal antibodies and high-throughput screening.
Stephen's commitment to innovation is evident in the key projects his group undertakes, where they not only focus on the production of therapeutic proteins but also contribute to the understanding of protein structure through advanced techniques such as X-ray crystallography. By integrating genomics and cutting-edge biotechnological methods, Stephen ensures that Amgen remains at the forefront of drug discovery, ultimately contributing to the development of novel therapeutics that can make a significant impact on patient care. His leadership and vision are instrumental in driving the success of Amgen's research endeavors, fostering collaboration across disciplines, and pushing the boundaries of what is possible in biotechnology.
